CASE REPORT

Acute hepatitis E presenting with clinical feature of autoimmune hepatitis

Ishan Patel, MBBS1*, Rafael Ching Companioni, MD2, Raghav Bansal, MD2, Neil Vyas, MD1, Carmine Catalano, MD1, Joshua Aron, MD2 and Aaron Walfish, MD2

1Internal Medicine, Icahn School of Medicine (Elmhurst) Program, Elmhurst, NY, USA; 2Gastroenterology, Icahn School of Medicine (Elmhurst) Program, Elmhurst, NY, USA

A 32-year-old immigrant man presented with new onset jaundice. His past medical history was significant for type 2 diabetes mellitus, hypertension, and hyperlipidemia. His initial laboratory finding and liver biopsy were suggestive of autoimmune hepatitis (AIH). The plan was to start steroids pending negative results for viral serology, but it came back positive for hepatitis E virus. The patient’s liver function test and clinical condition improved significantly on conservative management over a period of 1 month. Therefore, we suggest testing for hepatitis E especially in immigrants or recent travelers to endemic areas who presents with clinical features suggestive of AIH.

Keywords: hepatitis E; autoimmune hepatitis; transaminitis; IAIHG; hepatitis serologies

*Correspondence to: Ishan Patel, Internal Medicine, Icahn School of Medicine (Elmhurst) Program, 79-01 Broadway, Elmhurst, NY 11373, USA, Email: ishan811@gmail.com

A 32-year-old overweight non-alcoholic non-smoker Bengali man was admitted to our hospital with jaundice, nausea, non-bilious, non-bloody vomiting, and worsening malaise for 3 days. His past medical history was significant for type 2 diabetes mellitus, hypertension, and hyperlipidemia. He denied any sick contacts, use of herbs, or recent change in medications. His physical examination was significant for normal vital signs, scleral icterus, and without stigmata for chronic liver disease. Laboratory values on admission and during the hospital course are shown in Table 1. In our patient, initial workup revealed alkaline phosphatase (ALP)/aspartate transaminase (AST) with ratio 1.5, more than twofold increase in IgG, antinuclear antibody (ANA), and anti-smooth muscle antibody (ASMA) titer 1:80, anti-mitochondrial antibody (AMA) positive, negative drug history, and no alcohol intake. A liver biopsy performed showed lymphoplasmacytic portal inflammation with significant interface hepatitis and cholestasis (Figs. 1 and 2). These clinical findings added up to an International Autoimmune Hepatitis Group (IAIHG) score of 13 points. Because the patient emigrated from an endemic area for hepatitis E around 1 month prior to presentation, HEV IgM was checked, which subsequently returned positive. The test was performed by Focus Diagnostics, Inc. based out...
of San Juan Capistrano, CA, using enzyme linked immunosorbent assay method. The patient was treated with supportive care and closely monitored in an outpatient clinic. He improved clinically with significant improvement of his liver function tests over the next month.

Discussion
IAIHG developed a diagnostic scoring system, which outlined 13 criteria for the diagnosis of AIH in a majority of the patients. It included gender; ALP to AST or alanine transaminase (ALT) ratio; serum globulins or

Table 1. Laboratory values

|                     | Day 1  | Day 2  | Day 8  | Day 9  | Day 11 | Day 27 |
|---------------------|--------|--------|--------|--------|--------|--------|
| WBC (K/mcl)         | 7.9    | 8.6    | 5.3    | 642    | 573    | 346    |
| Platelets (K/mcl)   | 168    | 276    | 214    | 227    | 97     | 33     |
| AST (U/L)           | 1,249  | 1,096  | 1,082  | 797    | 378    | 38     |
| ALT (U/L)           | 152    | 148    | 138    | 121    | 94     | 76     |
| GGT                 | 235    | 203    | 109    | 93     | 74     | 45     |
| LDH                 | 419    | 396    | 221    | 160    | 126    | 155    |
| Albumin             | 4.0    | 3.6    | 4.1    | 3.7    | 3.2    | 4.1    |
| Total bilirubin     | 5.1    | 5.4    | 12.1   | 10.9   | 8.0    | 1.2    |
| Conj. bilirubin     | 3.1    | 3.2    | 7.2    | 6.7    | 4.5    | 0.6    |
| INR                 | 1.2    | 1.1    |        |        |        |        |
| PT                  | 13.3   | 11.6   |        |        |        |        |
| IgG                 |        |        |        | 3,590  | 2,330  |        |
| IgA                 |        |        |        | 318    | 233    |        |
| IgM                 |        |        |        | 199    | 148    |        |
| HAV IgM             |        |        |        |        |        |        |
| HBsAg               |        |        |        |        |        |        |
| HBsAb               |        |        |        |        |        |        |
| HBeAb               |        |        |        |        |        |        |
| HEV IgM             |        |        |        |        |        |        |
| HCV RNA PCR         |        |        |        |        |        |        |
| HSV DNA PCR         |        |        |        |        |        |        |
| CMV DNA PCR         |        |        |        |        |        |        |
| HIV                 |        |        |        |        |        |        |
| ANA                 | 1:1,280|        |        |        |        |        |
| ASMA                | 1:160  |        |        |        |        |        |
| AMA                 | 1:40   |        |        |        |        |        |

Fig. 1. Portal inflammation (vertical arrow) with interphase hepatitis and cholestasis (horizontal arrow).

Fig. 2. Portal inflammation containing plasma cell (arrow).
IgG levels; ANA, ASMA, or anti-liver-kidney microsome antibodies; AMA; hepatitis viral markers; drug history; average alcohol intake; liver histology; other autoimmune diseases; seropositivity for other defined autoantibodies; HLA DR3 or DR4; and response to therapy (6).

In our case, the IAIHG score of 13 points meets the criteria for ‘probable AIH’. Concomitantly, he was positive for anti-HEV IgM and IgG antibodies suggesting acute HEV infection. The pathophysiology of these concomitant presentations of AIH and HEV seroprevalence is not well understood. Several studies have reported the presence of anti-HEV IgG antibodies in patients with AIH suggesting that HEV infection may act as a possible trigger or hapten for the development of AIH (5). Similar to our case, AMA is found to be present in sera of patients with AIH more frequently than expected. However, the clinical significance of it remains unclear (7).

Several observations in our case suggest that HEV may have triggered an AIH response. Resolution of abnormal liver function test and clinical recovery in a short period of 6–8 weeks without any intervention is unlikely in patient with AIH (8). Liver biopsy showing signs of portal inflammation and cholestasis is characteristic of viral etiology. Serology tests were positive for HEV. Patient clinically improved and returned to his home country. Due to that, we were not able to send HEV PCR. HEV PCR is considered to be the most sensitive test for diagnosing acute HEV infection. However, a recent investigation showed a variable sensitivity for different HEV PCR assays (9). Similar cases with a concomitant presentation of HEV and autoimmune mimicry have been reported in the literature (10, 11).

This case illustrates the importance of excluding acute HEV in patients with criteria for ‘probable AIH’ from an endemic area. Empiric therapy for AIH may lead to protracted and unnecessary therapy. Effect of steroids in such cases, beneficial or harmful, is unclear given the paucity of data in the literature.

In conclusion, our case is unique as it shows that in-patients who are clinically stable and improving with conservative management, treatment with steroids should be delayed until HEV is appropriately ruled out.

Conflict of interest and funding

The authors declare that there is no conflict of interest regarding the publication of this article.

References

1. Emerson SU, Purcell RH. Running like water – The omnipre- sence of hepatitis E. N Engl J Med 2004; 351(23): 2367–8.
2. CDC. Division of Viral Hepatitis. Available from: http://www. cdc.gov/hepatitis/hev/hevfaq.htm [cited 30 October 2016].
3. Chandra NS, Ojha D, Chatterjee S, Chattopadhyay D. Pre- valence of hepatitis E virus infection in West Bengal, India: A hospital-based study. J Med Microbiol 2014; 63(Pt 7): 975–80.
4. Manka P, Bechmann LP, Coombes JD, Thodou V, Schlattjan M, Kahraman A, et al. Hepatitis E virus infection as a possible cause of acute liver failure in Europe. Clin Gastroenterol Hepatol 2015; 13(10): 1836–42.e2.
5. Pischke S, Gisa A, Suneetha PV, Wiegand SB, Taubert R, Schlue J, et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One 2014; 9(1): e85330.
6. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31(5): 929–38.
7. Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006; 21(9): 1448–54.
8. Czaja A. Features and consequences of untreated autoimmune hepatitis. Liver Int 2009; 29: 816–23.
9. Baylis SA, Hanschmann KM, Blümel J, Nübling CM. HEV Collaborative Study Group. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: An initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol 2011; 49(4): 1234–9.
10. Nagasaki F, Ueno Y, Kanno N, Okamoto H, Shimosegawa T. A case of acute hepatitis with positive autoantibodies who actually had hepatitis E virus infection. Hepatol Res 2005; 32(2): 134–7.
11. Vieira CL, Baldaia C, Fatela N, Ramalho F, Cardoso C. Case of acute hepatitis E with concomitant signs of autoimmunity. World J Hepatol 2013; 5(3): 152–5.